Skip to main content
Journal ArticleOPEN ACCESS

Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety

Frontiers in Pharmacology (2022) 12
DOI: 10.3389/fphar.2021.787239
4Citations
Citations of this article
25Readers
Mendeley users who have this article in their library.

Author supplied keywords

Cite

CITATION STYLE

APA

Isles, M. P. (2022). Nanomedicines and Nanosimilars—Why a Robust Centralised Regulatory Framework Is Essential to Enhance Patient Safety. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.787239

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free